Oral mucositis (severe) · breast cancer patients undergoing chemotherapy
Granulocyte-macrophage colony-stimulating factor (GM-CSF), higher… led to higher oral mucositis (severe) compared with granulocyte-macrophage colony-stimulating factor (GM-CSF), lower…; GRADE not reported.
1 finding from 1 review
Pain reduction (VAS 0-10) · People with erosive oral lichen planus
Topical tacrolimus 0.1% ointment showed no clear difference in pain reduction (VAS 0-10) compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Reduction in target/mean lesion size · People with erosive oral lichen planus
Topical tacrolimus 0.1% ointment showed no clear difference in reduction in target/mean lesion size compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Patient preference · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Patient preference for active sprays vs placebo nearly attained significance (Chi2 7.259, df=3; P = 0.064); 15/43 participants expressed no desire to continue any spray after the trial.
1 study · 43 participants
GRADE not reported
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Adverse events attributed to GM-CSF typically bone pain, nausea, fever and headache; not reported as serious; reporting poor and inconsistent (SoF comments cell, not GRADE-rated)
8 studies
GRADE not reported
Oral mucositis (any severity) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral mucositis (any severity) compared with placebo or no treatment; GRADE not reported.
2 findings from 1 review
Oral mucositis (severe) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral mucositis (severe) compared with placebo or no treatment (low certainty).
3 findings from 1 review
RR 0.74 [0.33, 1.67]
3 studies · 235 participants
Low
RR 0.59 [0.05, 7.11]
2 studies · 65 participants
Very low
RR 0.31 [0.01, 7.09]
1 study · 29 participants
Very low
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
It is very uncertain whether granulocyte-macrophage colony-stimulating factor (GM-CSF) changes oral mucositis (moderate to severe) compared with placebo or no treatment (very low certainty).
2 findings from 1 review
Oral pain · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral pain (mean pain score, 0 to 10 scale) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Number of days of treatment with opioid analgesics · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) led to lower number of days of treatment with opioid analgesics compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Normalcy of diet (tube feeding) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in normalcy of diet (tube feeding) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Granulocyte macrophage-colony stimulating factor (GM-CSF) led to higher improvement in mucositis compared with placebo or no treatment; GRADE not reported.
2 findings from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Granulocyte macrophage-colony stimulating factor (GM-CSF) showed no clear difference in time to heal mucositis (days) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Granulocyte macrophage-colony stimulating factor (GM-CSF) led to lower time to heal mucositis (days) compared with antimycotic mouthrinse; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Granulocyte macrophage-colony stimulating factor (GM-CSF) led to lower time to heal mucositis (days) compared with povidone iodine; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in interruptions to cancer treatment compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Normalcy of diet (percutaneous endoscopic gastrostomy) · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in normalcy of diet (percutaneous endoscopic gastrostomy) compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review